Martin R Stockler - JoVE Visualize

Showing results (81-90 of 167) with videos related to

Pageof 17

Sort By:

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2014

Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancerMadeleine T King, Martin R Stockler, Phyllis Butow, et al.

British Journal of Cancer|October 21, 2016

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, Prunella Blinman, Linda Mileshkin, et al.

The Journal of Clinical Investigation|September 17, 2024

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceNima Sharifi, Robert Diaz, Hui-Ming Lin, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022

The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 18, 2016

The role of mindfulness in distress and quality of life for men with advanced prostate cancerSuzanne K Chambers, Elizabeth Foley, Samantha Clutton, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled TrialSuzanne K Chambers, Stefano Occhipinti, Elizabeth Foley, et al.

Breast Cancer Research and Treatment|October 18, 2008

Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial)Michaella J Smith, P Grantley Gill, Neil Wetzig, et al.

The Oncologist|April 19, 2015

Regional variation in identified cancer care needs of early-career oncologists in China, India, and PakistanH Kim Lyerly, Maria R Fawzy, Zeba Aziz, et al.

The Lancet. Oncology|August 2, 2017

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Madeleine King, et al.

Kidney Cancer (Clifton, Va.)|February 12, 2019

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.

Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:

Pageof 17

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2014

Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancerMadeleine T King, Martin R Stockler, Phyllis Butow, et al.

British Journal of Cancer|October 21, 2016

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial, Prunella Blinman, Linda Mileshkin, et al.

The Journal of Clinical Investigation|September 17, 2024

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceNima Sharifi, Robert Diaz, Hui-Ming Lin, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022

The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 18, 2016

The role of mindfulness in distress and quality of life for men with advanced prostate cancerSuzanne K Chambers, Elizabeth Foley, Samantha Clutton, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled TrialSuzanne K Chambers, Stefano Occhipinti, Elizabeth Foley, et al.

Breast Cancer Research and Treatment|October 18, 2008

Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial)Michaella J Smith, P Grantley Gill, Neil Wetzig, et al.

The Oncologist|April 19, 2015

Regional variation in identified cancer care needs of early-career oncologists in China, India, and PakistanH Kim Lyerly, Maria R Fawzy, Zeba Aziz, et al.

The Lancet. Oncology|August 2, 2017

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Madeleine King, et al.

Kidney Cancer (Clifton, Va.)|February 12, 2019

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE TrialNicola J Lawrence, Andrew Martin, Ian D Davis, et al.

Pageof 17